Drug Trial Radar · NCT04188548
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
379
Actual
Start
Dec 10, 2019
Primary completion
Jun 29, 2020
Study completion Dec 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Dec 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
Conditions
- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Endometrial Cancer
Interventions
LY3484356Drug
Administered orally
AbemaciclibDrug
Administered orally
EverolimusDrug
Administered orally
AlpelisibDrug
Administered orally
TrastuzumabDrug
Administered intravenously
Aromatase Inhibitor (AI)Drug
Anastrozole or Exemestane or Letrozole administered orally (physician choice)
PertuzumabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent ToxicitiesTime frame: Baseline through Cycle 1 (21/28 Day Cycle)
Locations
74 sites in 8 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona
Highlands Oncology Group
Springdale, Arkansas
Beverly Hills Cancer Center
Beverly Hills, California
University of California, Irvine
Orange, California
UCSF Medical Center at Mission Bay
San Francisco, California
Mayo Clinic in Florida
Jacksonville, Florida
Lake Nona DDU
Orlando, Florida
Winship Cancer Center Emory University
Atlanta, Georgia
Community Cancer Center North
Indianapolis, Indiana
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Minnesota Oncology/Hematology PA
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Memorial Sloan Kettering - Bergen
Montvale, New Jersey
Memorial Sloan Kettering Cancer Center
Commack, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Wilmot Cancer Institute
Rochester, New York
Duke University
Durham, North Carolina
Ohio State University Medical Center
Columbus, Ohio
University of Oklahoma Health Sciences Center, Stephenson Cancer Center
Oklahoma City, Oklahoma
Asante Rogue Regional Medical Center
Medford, Oregon
UPMC Hillman Cancer Center Harrisburg
Harrisburg, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Vanderbilt Health One Hundred Oaks
Nashville, Tennessee
SCRI Oncology Partners
Nashville, Tennessee
Tennessee Oncology Nashville
Nashville, Tennessee
UT Southwestern Med Center
Dallas, Texas
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas
Minnesota Oncology/Hematology PA
The Woodlands, Texas
Oncology and Hematology Associates of Southwest Virginia Inc
The Woodlands, Texas
Texas Oncology - San Antonio Medical Center
The Woodlands, Texas
US Oncology
The Woodlands, Texas
USO-Rocky Mountain Cancer Center
The Woodlands, Texas
Texas Oncology - Tyler
Tyler, Texas
The University of Vermont Medical Center Inc.
Burlington, Vermont
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.